Opus Point Partners’ AUM, History and Investments

Page 7 of 7

6. Karyopharm Therapeutics Inc (NASDAQ:KPTI)

Opus Point Partners also added Karyopharm Therapeutics Inc (NASDAQ:KPTI) to its equity portfolio during the second quarter and reported a $905,000 stake that contained 100,000 shares in its latest 13F filing. William Leland Edwards’ Palo Alto Investors is another shareholder of Karyopharm Therapeutics, which owns 3.47 million shares as of the end of June.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a clinical-stage pharmaceutical company that develops drugs against nuclear transport and related targets for the treatment of cancer. It last reported a loss of $0.64 per share for the second quarter, which beat the consensus estimate, but its revenue amounted to just around $3,000 and was $117,000 lower than expected.

Disclosure: none

Page 7 of 7